Alphamab Oncology Ordinary Shares ALMOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.06
- Day Range
- $1.02–1.02
- 52-Week Range
- $1.02–1.06
- Bid/Ask
- $0.80 / $0.88
- Shares Outstanding
- 966.15M
- Market Cap
- $989.45M
- Volume/Avg
- 125 / 138
Key Statistics
- Price/Earnings (Normalized)
- 30.22
- Price/Sales
- 13.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.51%
Company Profile
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 515
- Website
- https://www.alphamabonc.com
Valuation
|
Metric
|
ALMOF
|
|---|---|
Price/Earnings (Normalized) | 30.22 |
Price/Book Value | 4.17 |
Price/Sales | 13.31 |
Price/Cash Flow | — |
Price/Earnings
ALMOF
Financial Strength
|
Metric
|
ALMOF
|
|---|---|
Quick Ratio | 3.68 |
Current Ratio | 4.02 |
Interest Coverage | −30.62 |
Quick Ratio
ALMOF
Profitability
|
Metric
|
ALMOF
|
|---|---|
Return on Assets (Normalized) | −6.61% |
Return on Equity (Normalized) | −8.69% |
Return on Invested Capital (Normalized) | −8.49% |
Return on Assets
ALMOF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>$f$^z | LOCK|@Y@q# | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!<Z!Fs | LOCK|J!Rz | $84B | |||
| Moderna Inc
MRNA
| LOCK|$%fw>s | LOCK|@YK | $81B | |||
| argenx SE ADR
ARGX
| LOCK|HlXffMj | LOCK|D>? | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<cjfkM< | LOCK|T< | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!@W?&$g | LOCK|%%@& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|zG#<xYG | LOCK|<GsG@ | $28B | |||
| Incyte Corp
INCY
| LOCK|kFtMsp& | LOCK|HY$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|&yZVB& | LOCK|j#Z | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ch?RJV | LOCK|Z?v | $14B |
United States